Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1986-10-2
|
pubmed:abstractText |
Characterization of the pharmacokinetics of 2-FLAA has been completed in seven patients receiving 18 or 25 mg/m2 daily X 5 of 2-FLAMP over 30 min. Assuming 2-FLAMP was instantaneously converted to 2-FLAA, the plasma levels of 2-FLAA declined in a biexponential fashion. Computer fitting of the plasma concentration-time curves yielded an average distribution half-life (t1/2 alpha) of 0.60 h and a terminal half-life (t1/2 beta) of 9.3 h. The estimated plasma clearance was 9.07 +/- 3.77 l/h per m2 and the steady state volume of distribution, 96.2 +/- 26.0 l/m2. There was a significant inverse correlation between the area under the curve (AUC) and absolute granulocyte count (r = -0.94, P less than 0.02). A relationship between creatinine clearance and total body clearance was noted, but was not statistically significant (r = 0.828; P less than 0.1). Approximately 24% +/- 3% of 2-FLAA was excreted renally over the 5-day course of drug administration.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Arabinonucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine Phosphate,
http://linkedlifedata.com/resource/pubmed/chemical/fludarabine monophosphate
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0344-5704
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
277-80
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:2427240-Agranulocytosis,
pubmed-meshheading:2427240-Antimetabolites, Antineoplastic,
pubmed-meshheading:2427240-Arabinonucleotides,
pubmed-meshheading:2427240-Biotransformation,
pubmed-meshheading:2427240-Chromatography, High Pressure Liquid,
pubmed-meshheading:2427240-Creatinine,
pubmed-meshheading:2427240-Female,
pubmed-meshheading:2427240-Humans,
pubmed-meshheading:2427240-Kinetics,
pubmed-meshheading:2427240-Male,
pubmed-meshheading:2427240-Metabolic Clearance Rate,
pubmed-meshheading:2427240-Middle Aged,
pubmed-meshheading:2427240-Vidarabine Phosphate
|
pubmed:year |
1986
|
pubmed:articleTitle |
Pharmacokinetic study of fludarabine phosphate (NSC 312887).
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|